bioRxiv (Cold Spring Harbor Laboratory)
July 13, 2026
Natasha L. Mason, Eline Chm Haijen-Bongers, Kim P. C. Kuypers et al.
Serotonergic psychedelics are advancing as psychiatric treatments, yet acute responses vary between individuals and the contribution of sex, a fundamental biological variable, remains largely unexamined. We pooled two double-blind, placebo-controlled studies in healthy volunteers (N = 72; 31 male, 41 female) comparing psilocybin 15 mg, 2C-B 20 mg, and LSD 50 μg. Linear mixed models tested sex...
Research Square
June 19, 2026
Aline Frick, Grace Blest‐hopley, Manesh Grin et al.
Abstract Rationale: Major depressive disorder (MDD) shows marked sex differences in prevalence, symptomatology, and treatment response. However, women remain underrepresented in many clinical trials, and sex-specific treatment outcomes are rarely examined. Objectives This study reanalyzed data from a randomized controlled trial comparing psilocybin and escitalopram for MDD to evaluate sex...
npj Mental Health Research
January 29, 2026
Eirini K. Argyri, Flora Fraser, Stefan Schilling et al.
Psychedelic substances are increasingly recognized for their potential to catalyse transformative shifts in worldviews. Central to these transformations may be the integration of self-transcendent states. This mixed-methods study explored transformative psychedelic experiences, focussing on subsequent epistemic shifts. Ninety participants completed the Awe Experience Scale (AWE-S), and the...
Research Square
March 31, 2025
Eirini K. Argyri, Flora Fraser, Stefan Schilling et al.
Abstract Psychedelic substances are increasingly recognized for their potential to catalyse transformative shifts in worldviews. Central to these transformations are states of awe, a self-transcendent, epistemic emotion. This mixed-methods study explored how awe during psychedelic trips relates to lasting changes in boundaries between self and world, and epistemic shifts that follow...